Ignite Creation Date:
2024-05-05 @ 11:45 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00120887
Status:
COMPLETED
Last Update Posted:
2007-04-05
First Post:
2005-07-12
Brief Title:
Lupus Atherosclerosis Prevention Study
Sponsor:
Johns Hopkins University
Organization:
Johns Hopkins University
Study Overview
Official Title:
Lupus Atherosclerosis Prevention Study
Status:
COMPLETED
Status Verified Date:
2006-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Cardiovascular disease specifically from atherosclerosis is the major cause of mortality in systemic lupus erythematosus SLE in developed countries Coronary artery disease and stroke contribute to long-term morbidity in surviving patients Atherosclerosis in SLE is multifactorial with immuneinflammatory endothelial damage traditional cardiovascular risk factors and prothrombotic factors all playing important roles Multiple groups have shown that hyperlipidemia is predictive of later atherosclerosis in SLE In the general population statins have become the drug of choice in preventing atherosclerotic events through two mechanisms lipid lowering that helps to prevent progression and stabilization of plaques to prevent rupture In the Lupus Atherosclerosis Prevention Trial we will determine if atorvastatin reduces the progression of atherosclerosis on helical computed tomography CT and carotid duplex Recent work has confirmed that statins have an immunomodulatory role This study will also determine whether statins improve clinical lupus activity or lupus serologies anti-dsDNA and complement
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None